The safety and efficacy of the c-Met inhibitor INC280 and cetuximab in comparison to cetuximab or the anti-EGFR antibody panitumumab were also analyzed in HNSCC patients whose disease progressed after cetuximab or panitumumab treatment (NCT02205398). The gene discussed is MET; the disease is head and neck squamous cell carcinoma.